Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 15, 2022 (5 years ago)

Diclofenac Sodium Topical Solution USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Diclofenac Sodium Topical Solution USP, 1.5% w/w, 5 fl. oz. (150 mL) bottles, Rx Only, Manufactured for: SOLA Pharmaceuticals, Baton Rouge, LA 70810, NDC 70512-025-05.

Affected NDC 70512-0025-05

Compare with the code on your package — it is the most precise check available.

Drug: Diclofenac Category: Pain Relief & OTC Medication

Recalling firm
Teligent Pharma, Inc.
NDC code
70512-025-05
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0680-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Diclofenac recalls

See all
Class II · Moderate risk

Diclofenac Sodium

Failed Viscosity Specifications: Out of Specification (OOS) [slightly lower than the limit] result in viscosity for Diclofenac Sodium Gel, 3%.

Ongoing Failed specification Sun Pharmaceutical Industries INC NDC 51672-1363-7 D-0342-2026
Class II · Moderate risk

Diclofenac Sodium Topical Solution 1.5% w/w

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Terminated Stability / shelf life Preferred Pharmaceuticals, Inc. NDC 68788-7918-01 D-0773-2022

Other recalls by Teligent Pharma, Inc.

All 2022 recalls
Class II · Moderate risk

Lidocaine Ointment USP

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 50383-341-35 D-0705-2022
Class II · Moderate risk

Lidocaine Cream 4%

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 0536-1281-28 D-0704-2022
Class II · Moderate risk

Hydrocortisone Butyrate Lotion

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 70512-032-04 D-0703-2022
Class II · Moderate risk

Gentamicin Sulfate Cream USP

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 70512-036-30 D-0702-2022